These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 2589933)

  • 1. [Therapeutic results and toxic side effects of the combination cytostasan, adriamycin and vincristine as second-line therapy of metastatic breast cancer].
    Brockmann B; Kirchhof I; Geschke E; Schmidt UM
    Arch Geschwulstforsch; 1989; 59(5):341-6. PubMed ID: 2589933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic results and toxic side effects of the cytostasan, adriamycin and vincristine combination as second line therapy in metastatic breast cancer].
    Brockmann B; Geschke E; Schmidt UM; Ebeling K
    Geburtshilfe Frauenheilkd; 1991 May; 51(5):383-6. PubMed ID: 1869008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
    Ruffert K
    Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations.
    Petru E; Schmähl D
    Wien Klin Wochenschr; 1986 Dec; 98(23):790-7. PubMed ID: 3811371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
    Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
    Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
    Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
    Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast Cancer in Japan].
    Nomura Y; Abe O; Izuo M; Inoue K; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1863-71. PubMed ID: 3382238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
    Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone.
    Tannir N; Yap HY; Hortobagyi GH; Hug V; Buzdar AU; Blumenschein GR
    Cancer Treat Rep; 1984; 68(7-8):1039-41. PubMed ID: 6547638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of adriamycin in the treatment of metastatic breast cancer].
    Dymarskiĭ LIu; Sanchakova AV; Aleksandrova GI; Trishkina EA
    Vopr Onkol; 1984; 30(6):67-73. PubMed ID: 6547554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy of metastasizing breast cancer].
    Wascher H
    Wien Med Wochenschr; 1985 Dec; 135(23-24):590-4. PubMed ID: 3841627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.
    Manni A; Trujillo JE; Pearson OH
    Cancer Treat Rep; 1980 Jan; 64(1):111-6. PubMed ID: 6155207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
    J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined drug/hormone therapy in metastatic breast cancer with vincristine, adriamycin, cyclophosphamide and high dose medroxyprogesterone acetate--VAC-MAP. Preliminary results of a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
    Wander HE; Nagel GA; Blossey HC; Kordilla F; Stamm S; Matthressen W; Weiss J
    Onkologie; 1982 Aug; 5 Suppl():8-12. PubMed ID: 6752794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.